American Society of Hematology, Dec. 11 to 14
The annual meeting of the American Society of Hematology was held from Dec. 11 to 14 in Atlanta and attracted participants from around the world, including hematology specialists as well as clinical practitioners and other health care professionals. The conference featured presentations focusing on the diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems.
In a phase 2 expansion cohort study, L. Elizabeth Budde, M.D., Ph.D., of the City of Hope Comprehensive Cancer Center in Duarte, California, and colleagues found that mosunetuzumab, a T-cell based bispecific antibody, is active in the outpatient setting among patients with relapsed or refractory follicular lymphoma who have received at least two prior lines of therapy.
The authors enrolled and treated 90 patients with follicular lymphoma with mosunetuzumab intravenously in a fixed duration, with one dose given every three cycles for eight cycles among patients who received a complete response and up to 17 cycles for patients who had a partial response or stable disease. Mosunetuzumab was administered using a step-up dosing strategy. The authors found mosunetuzumab demonstrated a complete response rate of 60 percent and an overall response rate of 80 percent. With a median follow up of 18.3 months, median progression-free survival was 17.3 months. The authors noted that most adverse events were of a low grade and transient.
“Mosunetuzumab has the potential to change the landscape of relapsed or refractory follicular lymphoma management,” Budde said. “It can be administered in the community setting with proper education and bring a pure immunotherapy to more patients.”
Several authors disclosed financial ties to pharmaceutical and biotechnology companies, including Genentech, which manufactures mosunetuzumab.
As part of the PROMISE study, Habib El-Khoury, M.D., of the Dana-Farber Cancer Institute in Boston, and colleagues found that screening using a higher-sensitivity novel approach allows for the detection of higher numbers of individuals with multiple myeloma, especially individuals who either self-identify as Black or have a family history of hematologic malignancy.
The authors analyzed blood samples from individuals ages 40 to 75 years who were considered at a higher risk for multiple myeloma because they were Black or had a family history of hematologic malignancy. Interim screening findings for 7,622 participants, including 2,439 Black individuals, were presented. The researchers found that higher-sensitivity novel matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (MS) performed better than conventional testing methods of serum protein electrophoresis and immunofixation at determining the prevalence of monoclonal gammopathy of undetermined significance (MGUS), a precursor condition to myeloma. The investigators found that the prevalence of MGUS in those at high risk older than 50 years of age was estimated to be around 13 percent by MALDI-TOF MS, which is higher than with conventional methods.
“In addition, using the higher-sensitivity MS, lower-level monoclonal gammopathies were detected (termed MGIP [monoclonal gammopathies of indeterminate potential]), which were lower than the limit of detection identified for the conventional methods (
Several authors disclosed financial ties to the pharmaceutical and biotechnology industries.
In the TRANSFORM study, Manali Kamdar, M.D., of the University of Colorado Cancer Center in Denver, and colleagues found that lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor T-cell therapy, significantly improves event-free survival (EFS) compared with standard of care among adults with relapsed or refractory large B-cell lymphoma (LBCL).
In a randomized, multicenter, phase 3 study, the authors evaluated liso-cel as a second-line treatment in adults with LBCL. Liso-cel was compared to salvage chemotherapy followed by high-dose chemotherapy plus autologous hematopoietic stem cell transplant, which has been the standard of care for second-line treatment of relapsed or refractory LBCL for more than 20 years. The researchers found that compared with the standard of care, liso-cel demonstrated statistically significant and clinically meaningful improvements in EFS, complete response rates, and progression-free survival. Median EFS was 10.1 months for liso-cel and 2.3 months for standard of care. No new safety signals for liso-cel were observed in the second-line setting.
“These results are potentially practice changing, as they challenge the treatment paradigm that has been in place for more than 20 years. The majority of patients who relapse after or are refractory to first-line LBCL treatment have poor outcomes with standard of care, with only 25 percent of transplant-eligible patients achieving long-term remission,” Kamdar said. “Results from TRANSFORM support the potential use of liso-cel as a new standard of care for the second-line treatment of patients with relapsed or refractory LBCL.”
Several authors disclosed financial ties to pharmaceutical and biotechnology companies, including Bristol Myers Squibb, the developer of liso-cel.
ASH: Axicabtagene Ciloleucel Slows Large B-Cell Lymphoma
TUESDAY, Dec. 21, 2021 (HealthDay News) — For patients with refractory or relapsed large B-cell lymphoma, axicabtagene ciloleucel leads to improvements in event-free survival and response compared with standard care, according to a study published online Dec. 11 in the New England Journal of Medicine and presented at the annual meeting of the American Society of Hematology, held from Dec. 11 to 14 in Atlanta.
ASH: Modified Regimen Slows Diffuse Large B-Cell Lymphoma
TUESDAY, Dec. 14, 2021 (HealthDay News) — For patients with diffuse large B-cell lymphoma, a modification of the regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, in which vincristine is replaced with polatuzumab vedotin, results in a lower risk for disease progression, relapse, or death, according to a study published online Dec. 14 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the American Society of Hematology, held from Dec. 11 to 14 in Atlanta.
Learn MoreFirst Long-Acting Injectable Approved for HIV PrEP
TUESDAY, Dec. 21, 2021 (HealthDay News) — The U.S. Food and Drug Administration has approved the first long-acting injectable treatment for HIV preexposure prophylaxis, which is given every two months and offers an alternative to daily oral medicatio…
Learn MoreBiden Outlines Measures to Fight Omicron, Pleads With Americans to Get Vaccinated
TUESDAY, Dec. 21, 2021 (HealthDay News) — President Joe Biden laid out a comprehensive plan on Tuesday to help Americans navigate a tough winter facing the omicron variant, but he also made an impassioned plea for every eligible person to get vaccine…
Learn MoreFDA Approves First-in-Class Treatment for Myasthenia Gravis
TUESDAY, Dec. 21, 2021 (HealthDay News) — Vyvgart (efgartigimod), a neonatal Fc receptor blocker (FcRn), was approved to treat generalized myasthenia gravis in adults who test positive for the anti-acetylcholine receptor (AChR) antibody, the U.S. Foo…
Learn MoreBiogen Cuts Price of Controversial Aduhelm in Half
TUESDAY, Dec. 21, 2021 (HealthDay News) — The maker of the pricey new drug for Alzheimer disease Aduhelm (aducanumab) said Monday it will slash the cost of its medication in half, effective Jan. 1, 2022.The move follows widespread criticism of the dr…
Learn MoreModerna Says Its Booster Protects Well Against Omicron
MONDAY, Dec. 20, 2021 (HealthDay News) — Moderna Inc. announced Monday that its COVID-19 vaccine booster shot significantly increased antibodies against the omicron variant.”The dramatic increase in COVID-19 cases from the omicron variant is concerni…
Learn MoreBiden to Address Nation Tuesday on Omicron Response, Outlook
MONDAY, Dec. 20, 2021 ( HealthDay News) — As COVID-19 cases start to surge once again across the United States, President Joe Biden will address the nation about the omicron variant on Tuesday.”Building off his Winter Plan, the President will announc…
Learn MoreProctor & Gamble Recalls Pantene, Herbal Essences Products Due to Benzene
MONDAY, Dec. 20, 2021 (HealthDay News) — Proctor & Gamble has voluntarily recalled several dry shampoo sprays and hair conditioner spray products with brand names Pantene, Herbal Essences, Aussie, and Waterless because of benzene contamination. This …
Learn More48 COVID-19 Cases Reported on World’s Largest Cruise Ship
MONDAY, Dec. 20, 2021 (HealthDay News) — At least 48 passengers and crew members on Royal Caribbean’s Symphony of the Seas — the world’s largest cruise ship — have tested positive for COVID-19 and have been quarantined, the company said Monday.Of t…
Learn MorePhysician’s Briefing Weekly Coronavirus Roundup
Here is what the editors at Physician’s Briefing chose as the most important COVID-19 developments for you and your practice for the week of Dec. 13 to 17, 2021. This roundup includes the latest research news from journal studies and other trusted sou…
Learn More